Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, "he didn't do it the way I would have, therefore, he is unprofessional"? Interesting take.
There is much to be excited about here. Much. Growing every day.
Long-haulers improved . . . what else do you need to know?
He said they don't comment on what the FDA is doing.
Gotta get my Blade & Bow with a block of ice ready for this one ... definitely a back porch, whiskey, and cigar kind of CC!
I expect some choppiness to develop shortly.
Good for you! I don't see you as sensitive (hell, I don't even know you), just raw honesty about whatever you're feeling at the moment. I can deal with that.
I did.
Of course, that is what they are "supposed" to do, did once during initial testing, but in NO way does the FDA guidelines indicate real-world experience with these tests. Linking to guidelines is just plain silly ...
Evidence?
the cumulative result
That's not only cynicism, it's skepticism too. But, I'd say the evidence is against you on that one . . . they have been steadily enrolling in every trial they have going, so why not this one? NASH is a big deal and awareness of it is growing across the globe.
The Raw Man stated:
it is likely none of the current U.S. testing methodologies yield any more than 5 false positives per 100 tests!
A study published in The BMJ has brought to light that the rapid finger-prick COVID-19 test may not be quite as reliable as previously thought — up to 1 in 5 people test “false positive”. This inaccuracy refers to a situation where someone who is not infected with SARS-CoV-2 tests positive for it.
Health experts say PCR testing - the most widely used diagnostic test for COVID-19 in the US - are too sensitive and need to be adjusted to rule out people who have insignificant amounts of the virus in their systems because they're likely not contagious.
They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.
The conclusion of their 34-page ruling included the following: “In view of current scientific evidence, this test shows itself to be unable to determine beyond reasonable doubt that such positivity corresponds, in fact, to the infection of a person by the SARS-CoV-2 virus.”
in order to protect the public,
I can't imagine that whatever DECN has developed would be any LESS accurate than these BS tests that are providing the media narrative with all the false positives they want . . .
It's good to see you all still here,
Investors had enough of their BS
What could they possibly deliver tomorrow? I mean it's not like the company has any great potential or anything, right? LOL It's only one of the best therapeutics in recent memory slugging its way through the minefield of regulatory BS.
My comment only referred to TDA's indications on the TOS platform. There is a closing trade price that is printed as the last trade when the market is open. Anything after that is not shown as the "closing" price, no matter the reason it printed after 4:00 EST.
The last trade was at 2.98, but the 3:00 close was at 3.27.
A 3-dollar bill could only be labeled "fake," if there were real 3-dollar bills.
Is it a real pink sheet non-filing entity?
What is it, then? Asking for a friend . . .
474,870,556 and 419,394,556 issued and outstanding as at Sep 30, 2020 and March 31, 2020 respectively
Nothing hidden. p. 3
Deep red sub penny by EOW
Moving target . . . keep guessing . . . you might get lucky.
Define "bug" (or big)
If you say it often enough you might eventually sync up with real-time events, but that won't make you right.
Just released on PR newswire, per TDA.
They ought to fix this on their official PR . . .
Exxe Group Reports Record Revenues for Quarter Ending September 30, 2020
2Q2021 revenues surpass record $7.7M set in 1Q2021
$8.2M 2Q2021 revenues increase 211% from $2.6M in 2Q2020
$15.8M revenue in 1H2021 increases 216% over 1H2020
AXXA reaffirms FY-2021 $30.8M revenue target
They compare 2021 to 2020 all throughout the document . . .
The quarterly reported all the information, but not sure about this PR. Hopefully, the real sleuths at TDA will get back to me. Don't have time to dig any deeper just now.
There are some suspicious "typos" in the PR on iHub - comparing quarters in 2021 . . .
Hell, it's not even on the company IR page!
https://exxegroup.com/investor-relations/
I just informed TDA to post it - they've sent the request to their 3rd party vendor for verification.
This will be back down in the .008 area by the end of the week.
Blew that one . . .
I concur. What multiple are you guys using for P/E?
Total shares outstanding: 474,870,556 million on 9/30/2020
Financial Statement 10-Q 11/19, p.3
What does tomorrow hold? More manipulation or the start of something awesome?
If the O/S remains where it is, the Conversion Price is $15M/841M or .0178.
Conversion number of shares per 1 Preferred is $100 (stated value)/conversion price (.0178) = 5,617.
So, conversion rate is 1:5,617 assuming current numbers.
Conversion Price. The conversion price (the “Conversion Price”) for the Preferred Stock (i) prior to a Qualified Financing shall equal the quotient resulting from dividing (x) $15,000,000 by (y) the number of Fully Diluted Securities determined as of the time of conversion (“FDS Conversion Price”), and (ii) upon and following a Qualified Financing shall be equal the lesser of (a) eighty percent (80%) of the lowest per share purchase price of Common Stock in a Qualified Financing (“QF Conversion Price”) and (b) the FDS Conversion Price determined immediately prior to the completion of a Qualified Financing.
a) Conversions at Option of Holder. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof (“Optional Conversion”), into that number of shares of Common Stock (subject to the limitations set forth in Section 6(e)) determined by dividing the Stated Value of such share of Preferred Stock plus accrued and unpaid dividends thereon, if any, by the Conversion Price.
Money is starting to move. From $4k to $1M cash on 10K Pref. B shares . . hello!
On October 22, 2020, Force Protection Video Equipment Corp., Inc. (“the Company”) entered into a Securities Purchase Agreement and Registration Rights Agreement with an accredited investor pursuant to which the investor agreed to purchase 10,000 shares of the Company's newly created Series B Preferred stock for $1,000,000 or $100 per share. The Company received the $1,000,000 on October 23, 2020. Those funds cannot be used by the Company until the share exchange transaction with SRAX (previously filed with the SEC on Form 8-K on October 5, 2020) has been closed
Very nice work, @hot_karl!
whoever is "StickyMaster" definitely sticky this one!